Status:

UNKNOWN

Radical Resection and HIPEC for Recurrent Retroperitoneal Sarcoma

Lead Sponsor:

National Cancer Centre, Singapore

Conditions:

Retroperitoneal Sarcoma

Eligibility:

All Genders

21+ years

Phase:

NA

Brief Summary

Retroperitoneal sarcoma is a rare cancer that accounts for 15% of soft tissue sarcomas and affects many young people. In approximately 50% of patients, the tumour will reappear in the same area regard...

Eligibility Criteria

Inclusion

  • Disease Characteristics
  • Histologically proven soft tissue sarcoma of one of following high-risk groups:
  • Tumours with grade 2 or 3 histology
  • Size more than or equal to 5cm
  • Extracompartmental and deep extension
  • Local recurrence of primary tumour
  • Inadequate surgical excision of previously operated on tumour
  • Proven diagnosis of recurrent retroperitoneal sarcoma confirmed by imaging modality and/ or intraoperative biopsy
  • Patient Characteristics
  • Age: ≥21 years old
  • Performance status: ECOG 0-1
  • Normal haematological, hepatic, coagulation, renal and electrolyte profiles
  • Normal left ventricular ejection fraction
  • Not pregnant or nursing

Exclusion

  • Patient is medically unfit for surgery due to concurrent medical comorbidities.
  • Any medical or psychiatric condition(s) which would preclude informed consent.
  • Patient is pregnant or nursing.

Key Trial Info

Start Date :

July 23 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 31 2024

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT03792867

Start Date

July 23 2018

End Date

March 31 2024

Last Update

October 11 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National Cancer Centre Singapore

Singapore, Singapore, 169610